课题基金 / 基金详情

TYPE V COLLAGENASE IN RHEUMATOID ARTHRITIS

TYPE V COLLAGENASE IN RHEUMATOID ARTHRITIS
类风湿性关节炎中的 V 型胶原酶
批准号:
3457710
负责人:
TAYEBEH POURMOTABBED
金额:
$9.98万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-02-01 至 1997-01-31

项目摘要

项目成果

TAYEBEH POURMOTABBED的其他基金

相似基金

相关文献

中文摘要
翻译
细胞外基质的降解需要协调的 构成金属蛋白酶家族的酶的作用。 的 组成这个家族的酶是相关的,因为它们被释放 从细胞中以潜伏形式,它们含有锌,需要二价 生物活性的阳离子。 总之,这些酶具有 降解细胞外基质几乎所有成分的能力。 这种降解能力在类风湿性关节炎中最为明显, 关节炎 在这种疾病中,金属蛋白酶的过度产生 介导关节软骨和软骨下骨的降解, 导致严重畸形。 V型胶原酶是其中的一员。 多基因酶家族,其对变性的 胶原,降解天然V型胶原并切割Xi型胶原 它是软骨的结构成分。 的主要目标 拟议的研究是了解这种酶的调节, 明确其在类风湿关节炎中的确切作用和意义。 为了实现这一目标,我们建议1。机理研究 通过鉴定V型胶原酶中的序列, 负责这一过程的酶的结构,使用定点 诱变和NMR光谱法。 这将通过生成一个 保守氨基酸序列(PRCGVPD)中的一系列突变, 评估取代对酶潜伏期的影响, 构象 与催化剂相互作用的氨基酸侧链部分 锌离子将通过113 Cd-NMR光谱进行鉴定和确认, Cd取代的野生型和突变型酶,2.检查函数, 推测的活性中心残基在催化中的重要性, 配体结合 一系列的突变会在活性位点产生 将测定潜在酶和重组突变酶的活性 因为它们具有降解和/或结合V型和Xi型胶原的能力 印刷受体. 将评估突变蛋白的能力, 结合Zn 2+和Ca 2+,二价阳离子结合将与 酶活性和底物结合。 Ca离子数 将通过NMR光谱测定与酶相关的分子量,3. 鉴定起活性碱催化剂作用的酸性氨基酸 通过定点突变和X射线晶体学 和4.研究纤连蛋白结合域的作用, 胶原样结构域在V型胶原酶底物特异性中的作用 产生缺失突变体并构建嵌合蛋白, 中性粒细胞胶原酶/V型胶原酶。 这些研究将进一步 我们对这种酶的作用的理解,并可能导致新的 治疗方法,将重点放在保护关节 类风湿性关节炎的组织退化。
英文摘要
The degradation of the extracellular matrix requires the coordinated action of enzymes which constitute a family of metalloproteinases. The enzymes which make up this family are related in that they are released from the cell in a latent form, they contain zinc and require divalent cations for biological activity. Together, these enzymes have the ability to degrade virtually all components of the extracellular matrix. Nowhere is this degradative ability more apparent than in rheumatoid arthritis. In this disease, excessive production of metalloproteinases mediates the degradation of articular cartilage and subchondral bone, resulting in severe deformity. Type V collagenase is a member of this multigene family of enzymes which exhibits high specificity for denatured collagen, degrades native type V collagen and cleaves type XI collagen which is a structural component of cartilage. The main objective of the proposed research is to understand the regulation of this enzyme and to define its precise role and significance in rheumatoid arthritis. Towards the achievement of this goal we propose to 1. study the mechanism of activation of type V collagenase by identifying the sequences in the structure of the enzyme responsible for this process using site-directed mutagenesis and NMR spectroscopy. This will be done by generating a series of mutations in the conserved amino acid sequence (PRCGVPD) and assessing the effect of the substitutions on enzyme latency and conformation. Amino acid side chain moieties interacting with catalytic zinc ion will be identified and confirmed by 113Cd-NMR spectroscopy of Cd-substituted wild type and mutant enzymes, 2. examine the function and significance of the presumptive active site residues in catalysis and ligand binding. A series of mutations will be created in the active site of the latent enzyme and the recombinant mutant enzymes will be assayed for their ability to degrade and/or bind to type V and XI collagen substrates. The mutant proteins will be evaluated for their ability to bind Zn2+ and Ca2+ and divalent cation binding will be correlated with enzymatic activity and substrate binding. The number of Ca ions associated with the enzyme will be determined by NMR spectroscopy, 3. identify the acidic amino acids that function as the active base catalyst in this enzyme by site-directed mutagenesis and X-ray crystallography and, 4. investigate the role of the fibronectin binding domain and collagen-like domain in substrate specificity of type V collagenase by generating deletion mutants and constructing chimeric proteins of neutrophil collagenase/type V collagenase. These studies will further our understanding on the action of this enzyme and may lead to new therapeutic approaches which would focus on protection of articular tissues from degradation in rheumatoid arthritis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of DNAzyme Gene Therapy for Huntington's Disease
Targeting Glioma by Anti-MMPs-2 and -9 DNAzymes
Targeting Glioma by Anti-MMPs-2 and -9 DNAzymes
Targeting Glioma by Anti-MMPs-2 and -9 DNAzymes
海外基金